INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity

2025-05-15 17:28:04 ET

Summary

• I rate INmune Bio, Inc. a speculative Strong Buy for high-risk investors, hinging on XPro's upcoming Phase II results in early Alzheimer's disease.
• XPro's unique mechanism targets neuroinflammation without ARIA risk, potentially serving 70% of early AD patients and outperforming current therapies.
• INMB's short cash runway makes positive XPro data critical for future funding, partnerships, or acquisition; failure could force shareholder dilution.
• Wall Street consensus is bullish with a $23.4 price target, but investors must manage risk given INMB's binary outcome and sector headwinds.

Background

INmune Bio, Inc. ( INMB ) announced Q1 2025 business and financial results on May 8th, 2025, beating the analyst’s estimates. More importantly, the company claims to be on track for sharing results of the MINDFul Phase II clinical trial in the second half of June ....

Read the full article on Seeking Alpha

For further details see: